Etanercept Market to Observe Strong Development by 2026
Etanercept is an injectable drug prescribed for the treatment of autoimmune diseases such as spondylitis and arthritis. Tumor necrosis factor (TNF alpha) is a protein manufactured during inflammation, the body's response to injury. TNF alpha protein stimulates inflammation and related signs such as tenderness and swelling. Etanercept is a man-made protein that binds TNF cascade and prevents the TNF alpha from stimulating inflammatory factors. In November 1998, the U.S. Food and Drug Administration (FDA) approved etanercept. Research findings suggest that...
View full press release